Physician profile
Robert Fan
NPI 1275604480
$22,080.06
in general payments reported to CMS, 2019-2025
43 companies · $5,675 in 2025
The $5,675 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,695 · 2020: $1,725 · 2021: $1,298 · 2022: $2,094 · 2023: $1,311 · 2024: $8,283 · 2025: $5,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,569 · Consulting Fee: $5,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,568.56 |
| Consulting Fee | $5,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $5,700.00 | 2024 | |
| Abbvie INC. | $2,791.40 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,212.29 | 2020-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $1,902.83 | 2019-2025 | Vemlidy, Trodelvy, Yeztugo |
| Pfizer INC. | $1,606.46 | 2019-2025 | |
| Janssen Biotech, INC. | $980.02 | 2020-2025 | Tremfya, Stelara, Rybrevant |
| Celgene Corporation | $748.72 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $746.01 | 2021-2025 | Cobenfy, Zeposia |
| Madrigal Pharmaceuticals | $662.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $313.13 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $302.62 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $275.15 | 2020-2025 | Entyvio |
| Pharmacosmos Therapeutics INC. | $268.02 | 2025 | Monoferric, Cosela |
| Shionogi INC | $266.17 | 2019-2025 | Fetroja |
| Teva Pharmaceuticals USA, INC. | $259.70 | 2024-2025 | Austedo Xr |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.